^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    polyvalent vaccine-KLH conjugate

    i
    Associations
    News

    Trials

    Company:
    MabVax
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission (NCT00693342)
    Phase 3
    Gynecologic Oncology Group
    Withdrawn
    Last update posted :
    02/24/2020
    MUC16
    |
    polyvalent vaccine-KLH conjugate
    Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab (NCT01223235)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    06/12/2018
    Initiation :
    10/01/2010
    Primary completion :
    09/01/2017
    Completion :
    09/01/2017
    ALK • MUC16
    |
    MUC16 elevation
    |
    Avastin (bevacizumab) • polyvalent vaccine-KLH conjugate